vs
通用电气医疗（OPCH）与Rollins, Inc.（ROL）财务数据对比。点击上方公司名可切换其他公司
通用电气医疗的季度营收约是Rollins, Inc.的1.6倍（$1.4B vs $906.4M），Rollins, Inc.净利率更高（11.9% vs 3.6%，领先8.3%），通用电气医疗同比增速更快（12.2% vs 10.2%），通用电气医疗自由现金流更多（$130.2M vs $111.2M），过去两年通用电气医疗的营收复合增速更高（13.0% vs 0.8%）
通用电气医疗是总部位于美国伊利诺伊州芝加哥的医疗科技企业，旗下设四大业务板块：医学影像（含分子成像、CT、磁共振、女性健康筛查及X线设备）、超声、患者护理解决方案（覆盖远程患者监测、麻醉呼吸护理、心脏病诊断、婴儿护理等）及制药相关业务。
Rollins, Inc.是北美知名虫害防治服务商，面向住宅及商业客户提供专业防控服务。公司依托Orkin、HomeTeam Pest Defense等多家全资子公司布局全球业务，覆盖北美、英国等市场，在民用及商用虫害治理领域具备深厚的行业积累与品牌优势。
OPCH vs ROL — 直观对比
营收规模更大
OPCH
是对方的1.6倍
$906.4M
营收增速更快
OPCH
高出2.0%
10.2%
净利率更高
ROL
高出8.3%
3.6%
自由现金流更多
OPCH
多$19.0M
$111.2M
两年增速更快
OPCH
近两年复合增速
0.8%
损益表 — Q3 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.4B | $906.4M |
| 净利润 | $51.8M | $107.8M |
| 毛利率 | 19.0% | — |
| 营业利润率 | 5.9% | 16.1% |
| 净利率 | 3.6% | 11.9% |
| 营收同比 | 12.2% | 10.2% |
| 净利润同比 | -3.8% | 2.5% |
| 每股收益（稀释后） | $0.32 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OPCHROL
| Q1 26 | — | $906.4M | ||
| Q4 25 | — | $912.9M | ||
| Q3 25 | $1.4B | $1.0B | ||
| Q2 25 | $1.4B | $999.5M | ||
| Q1 25 | $1.3B | $822.5M | ||
| Q4 24 | $1.3B | $832.2M | ||
| Q3 24 | $1.3B | $916.3M | ||
| Q2 24 | $1.2B | $891.9M |
净利润OPCHROL
| Q1 26 | — | $107.8M | ||
| Q4 25 | — | $116.4M | ||
| Q3 25 | $51.8M | $163.5M | ||
| Q2 25 | $50.5M | $141.5M | ||
| Q1 25 | $46.7M | $105.2M | ||
| Q4 24 | $60.1M | $105.7M | ||
| Q3 24 | $53.9M | $136.9M | ||
| Q2 24 | $53.0M | $129.4M |
毛利率OPCHROL
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 19.0% | — | ||
| Q2 25 | 19.0% | — | ||
| Q1 25 | 19.7% | — | ||
| Q4 24 | 21.3% | — | ||
| Q3 24 | 20.1% | — | ||
| Q2 24 | 20.3% | — |
营业利润率OPCHROL
| Q1 26 | — | 16.1% | ||
| Q4 25 | — | 17.5% | ||
| Q3 25 | 5.9% | 21.9% | ||
| Q2 25 | 5.8% | 19.8% | ||
| Q1 25 | 5.9% | 17.3% | ||
| Q4 24 | 6.9% | 18.1% | ||
| Q3 24 | 6.7% | 20.9% | ||
| Q2 24 | 6.6% | 20.4% |
净利率OPCHROL
| Q1 26 | — | 11.9% | ||
| Q4 25 | — | 12.8% | ||
| Q3 25 | 3.6% | 15.9% | ||
| Q2 25 | 3.6% | 14.2% | ||
| Q1 25 | 3.5% | 12.8% | ||
| Q4 24 | 4.8% | 12.7% | ||
| Q3 24 | 4.2% | 14.9% | ||
| Q2 24 | 4.3% | 14.5% |
每股收益（稀释后）OPCHROL
| Q1 26 | — | $0.22 | ||
| Q4 25 | — | $0.24 | ||
| Q3 25 | $0.32 | $0.34 | ||
| Q2 25 | $0.31 | $0.29 | ||
| Q1 25 | $0.28 | $0.22 | ||
| Q4 24 | $0.36 | $0.22 | ||
| Q3 24 | $0.31 | $0.28 | ||
| Q2 24 | $0.30 | $0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $309.8M | $116.5M |
| 总债务越低越好 | $1.2B | $650.6M |
| 股东权益账面价值 | $1.4B | $1.4B |
| 总资产 | $3.5B | $3.2B |
| 负债/权益比越低杠杆越低 | 0.86× | 0.47× |
8季度趋势，按日历期对齐
现金及短期投资OPCHROL
| Q1 26 | — | $116.5M | ||
| Q4 25 | — | $100.0M | ||
| Q3 25 | $309.8M | $127.4M | ||
| Q2 25 | $198.8M | $123.0M | ||
| Q1 25 | $171.4M | $201.2M | ||
| Q4 24 | $412.6M | $89.6M | ||
| Q3 24 | $483.0M | $95.3M | ||
| Q2 24 | $376.9M | $106.7M |
总债务OPCHROL
| Q1 26 | — | $650.6M | ||
| Q4 25 | — | $486.1M | ||
| Q3 25 | $1.2B | $485.7M | ||
| Q2 25 | $1.1B | $485.3M | ||
| Q1 25 | $1.1B | $485.5M | ||
| Q4 24 | $1.1B | $395.3M | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.1B | — |
股东权益OPCHROL
| Q1 26 | — | $1.4B | ||
| Q4 25 | — | $1.4B | ||
| Q3 25 | $1.4B | $1.5B | ||
| Q2 25 | $1.4B | $1.4B | ||
| Q1 25 | $1.4B | $1.4B | ||
| Q4 24 | $1.4B | $1.3B | ||
| Q3 24 | $1.4B | $1.3B | ||
| Q2 24 | $1.4B | $1.2B |
总资产OPCHROL
| Q1 26 | — | $3.2B | ||
| Q4 25 | — | $3.1B | ||
| Q3 25 | $3.5B | $3.2B | ||
| Q2 25 | $3.4B | $3.2B | ||
| Q1 25 | $3.3B | $2.9B | ||
| Q4 24 | $3.4B | $2.8B | ||
| Q3 24 | $3.4B | $2.8B | ||
| Q2 24 | $3.3B | $2.8B |
负债/权益比OPCHROL
| Q1 26 | — | 0.47× | ||
| Q4 25 | — | 0.35× | ||
| Q3 25 | 0.86× | 0.32× | ||
| Q2 25 | 0.82× | 0.34× | ||
| Q1 25 | 0.82× | 0.36× | ||
| Q4 24 | 0.79× | 0.30× | ||
| Q3 24 | 0.78× | — | ||
| Q2 24 | 0.79× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $139.4M | $118.4M |
| 自由现金流经营现金流 - 资本支出 | $130.2M | $111.2M |
| 自由现金流率自由现金流/营收 | 9.1% | 12.3% |
| 资本支出强度资本支出/营收 | 0.6% | 0.8% |
| 现金转化率经营现金流/净利润 | 2.69× | 1.10× |
| 过去12个月自由现金流最近4个季度 | $220.7M | $621.1M |
8季度趋势，按日历期对齐
经营现金流OPCHROL
| Q1 26 | — | $118.4M | ||
| Q4 25 | — | $164.7M | ||
| Q3 25 | $139.4M | $191.3M | ||
| Q2 25 | $90.3M | $175.1M | ||
| Q1 25 | $-7.2M | $146.9M | ||
| Q4 24 | $36.1M | $188.2M | ||
| Q3 24 | $160.4M | $146.9M | ||
| Q2 24 | $195.7M | $145.1M |
自由现金流OPCHROL
| Q1 26 | — | $111.2M | ||
| Q4 25 | — | $159.0M | ||
| Q3 25 | $130.2M | $182.8M | ||
| Q2 25 | $81.2M | $168.0M | ||
| Q1 25 | $-16.6M | $140.1M | ||
| Q4 24 | $25.8M | $184.0M | ||
| Q3 24 | $150.7M | $139.4M | ||
| Q2 24 | $185.9M | $136.4M |
自由现金流率OPCHROL
| Q1 26 | — | 12.3% | ||
| Q4 25 | — | 17.4% | ||
| Q3 25 | 9.1% | 17.8% | ||
| Q2 25 | 5.7% | 16.8% | ||
| Q1 25 | -1.2% | 17.0% | ||
| Q4 24 | 2.0% | 22.1% | ||
| Q3 24 | 11.8% | 15.2% | ||
| Q2 24 | 15.1% | 15.3% |
资本支出强度OPCHROL
| Q1 26 | — | 0.8% | ||
| Q4 25 | — | 0.6% | ||
| Q3 25 | 0.6% | 0.8% | ||
| Q2 25 | 0.6% | 0.7% | ||
| Q1 25 | 0.7% | 0.8% | ||
| Q4 24 | 0.8% | 0.5% | ||
| Q3 24 | 0.8% | 0.8% | ||
| Q2 24 | 0.8% | 1.0% |
现金转化率OPCHROL
| Q1 26 | — | 1.10× | ||
| Q4 25 | — | 1.41× | ||
| Q3 25 | 2.69× | 1.17× | ||
| Q2 25 | 1.79× | 1.24× | ||
| Q1 25 | -0.15× | 1.40× | ||
| Q4 24 | 0.60× | 1.78× | ||
| Q3 24 | 2.98× | 1.07× | ||
| Q2 24 | 3.69× | 1.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OPCH
| Commercial Customer | $1.3B | 87% |
| Government Customer | $172.8M | 12% |
| Patient Customer | $10.1M | 1% |
| Corporate Joint Venture | $1.9M | 0% |
ROL
暂无分部数据
